Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026. Participation details are as follows: Crohn’s & Colitis Congress® 2026January 22–24, 2026 | Las Vegas, NV Poster PresentationSession: Poster Hall ReceptionDate & Time: Friday, January 23, 2026, 5:00 PM – 6:30 PM PTTitle: PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis Through Gut-Selective Lymphocyte DepletionPresent
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio (NASDAQ:PALI) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108GlobeNewswire
- Palisade Bio (NASDAQ:PALI) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PALI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.MarketBeat
PALI
Sec Filings
- 1/13/26 - Form 4
- 12/8/25 - Form SCHEDULE
- 12/4/25 - Form 8-K
- PALI's page on the SEC website